Literature DB >> 30613342

In Vitro Ligand Binding Kinetics Explains the Pharmacokinetics of [18F]FE-PE2I in Dopamine Transporter PET Imaging.

Siim Kukk1,2, Olavi Loog2, Jukka-Veli Hiltunen2, Jaak Järv1,2.   

Abstract

Two of the most popular positron emission tomography (PET) tracers, [11C]PE2I and [18F]FE-PE2I, used to quantify dopamine transporters (DAT), display dissimilar kinetic behavior in in vivo assays. This difference can be explained by comparing values of kinetic rate constants, which characterize interaction of these tracers with DAT sites in vitro. At the same time, this kinetic analysis showed that the overall binding mechanism is similar for these two tracers and includes a fast step of complex formation followed by a slow isomerization step of this complex. Comparison with previous PE2I data revealed that isomerization of the DAT complex with PE2I occurs three times faster than in the case of FE-PE2I, which leads to the slower onset of peak specific binding of the former tracer in the DAT-rich regions. Therefore, ligands with slower isomerization on-rate, including [18F]FE-PE2I, seem to be better tracers in vivo, and their properties can be predicted in vitro.

Entities:  

Year:  2018        PMID: 30613342      PMCID: PMC6295847          DOI: 10.1021/acsmedchemlett.8b00504

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  1 in total

1.  [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism.

Authors:  Lisbeth Marner; Kirsten Korsholm; Lasse Anderberg; Markus N Lonsdale; Mads Radmer Jensen; Eva Brødsgaard; Charlotte L Denholt; Nic Gillings; Ian Law; Lars Friberg
Journal:  EJNMMI Res       Date:  2022-09-07       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.